Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus SUPRAX.
CEFOXITIN IN PLASTIC CONTAINER vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, and PBP2, thereby inhibiting transpeptidation and leading to cell lysis. It is a cephamycin antibiotic resistant to beta-lactamase hydrolysis due to a 7-alpha-methoxy group.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 6-8 hours; maximum 12 g/day
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.5 hours (approximately 45-90 minutes); prolonged to 2-6 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Renal: 85-95% unchanged via glomerular filtration and tubular secretion; biliary: <2%; fecal: trace.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic